Blocking TNF production could offer a more effective solution for the treatment of COVID-19.
EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, partnered with WorldQuant Predictive (WQP), a market leader in quantitative predictions and data-driven decisions through a cloud-based artificial intelligence (AI) platform, to improve the end result for patients.
MJH Life Sciences™ Launches COVID-19 Coalition — Alliance of renowned thought leaders to assemble biweekly to keep health care professionals abreast of emerging COVID-19 science and news. September 10, 2020 11:46 AM Eastern Daylight Time CRANBURY, N.J.–(BUSINESS WIRE)–MJH Life Sciences™, the privately owned health care media company, is pleased to officially announce […]
The age of blockbuster drugs has officially given way to precision medicines that are customized for rare diseases and individual patients. We are in the early days of a decades-long trend that will influence changes throughout the entire life sciences industry and lead to groundbreaking cures and treatments.
The U.S. Centers for Medicare and Medicaid Services finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc. and Novartis AG.
Johnson & Johnson plunked down $3.4 billion in cash to acquire privately held Auris Health Inc., a company that has developed robotic endoscopic technologies for the treatment of lung cancer.
Predictive analytics have transformed the way the telecom industry communicates with existing customers and distributes its resources to maximize customer retention. Can healthcare companies leverage the same analytics techniques to combat patient non-adherence?
The live video, real-time communications company (RTC) TokBox announced the results of its inaugural “Live Video Maturity Study.”
Outcome Health, which provides health intelligence in moments of care to improve patient outcomes, announced the hiring of its first Chief Engineering Officer, Nandini Ramani.
Outcome Health announced a financing round valuing the company at $5 billion pre-money, to expand its impact from 20% to 70% of all U.S. physician practices by 2020.